|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.031 - 0.033|
|52 Week Range||0.018 - 1.400|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Kasten shareholders are now well positioned for growth in 2018 and beyond. This was done concurrent with the merger of Kasten and DAKOTA Life Sciences. The second event was the filing of a federal lawsuit against infringers of intellectual property and contract violations.
SIOUX FALLS, S.D., Feb. 26, 2018 /PRNewswire/ -- In mid-2017, Kasten, Inc. (KAST) joined OPD Holdings, LLC, as a Co-Plaintiff in a South Dakota federal district court lawsuit against several people and entities throughout the United States involving numerous business and intellectual property claims. The claims were then amended more specifically toward Defendant Howard Phillips and his companies in Oklahoma, Christopher Ayo Otiko in California and his company Viaderma, LLC, (VDRM) also of California.
On December 21, 2017, the Company received an email from OTC Markets Group stating that at OTC Markets' discretion, they had labeled Kasten as Caveat Emptor on the OTCMarkets.com website. This was due to concerns with ongoing promotional activity.
SIOUX FALLS, S.D., Dec. 21, 2017 /PRNewswire/ -- Kasten Inc. (KAST) d/b/a DAKOTA Life Sciences has adopted blockchain technology for its new global drug protection software and information technology suite. Blockchain is a type of incorruptible digital ledger that was originally designed for managing crypto-currency transactions, such as Bitcoin. The new software suite is designed to provide global protection for users of critical pharmaceuticals and enhanced logistics chain reliability.
Kasten Inc. (OTC Pink: KAST)/DAKOTA Life Sciences, a division of Kasten Corporation, has announced its regulatory plan for its first prescription product to reduce the dangers of foot ulcers among those patients with diabetes, pre-diabetes or other immuno-compromising medical conditions. In the United States alone, there are over 26 million diabetics, 80 million pre-diabetics and an estimated additional 20 million immuno-compromised people at risk of small cuts or abrasions on their feet or lower legs rapidly leading to serious ulcers and infected wounds. Kasten's DAKOTA Life Sciences has developed and internationally tested a product that will be for prescription use in the United States, following successful completion of the required FDA protocols and trials.
In the area of topical delivery of medications through soft tissue, one of these technologies is known as Site Specific Penetration Technology (SSPT[TM]). This DAKOTA Life Sciences' drug delivery technology enables direct application of medications at the site where the drug is needed, rather than relying on delivery systemically through the blood stream.
Kasten's DAKOTA Life Sciences has now received a letter of financial support approval from Commissioner Catherine H. Smith of the Connecticut Department of Economic Development (DECD). This support is comprised of an initial $100,000 Small Business Express Matching Grant and a Small Business Express Job Creation Incentive loan in the amount of up to $299,000. "We are quite pleased to partner with the State of Connecticut and the City of Bridgeport," according to Steven Keough, the President of Kasten and Chief Operating Officer of DAKOTA Life Sciences.
Kasten, Inc. (OTC Pink: KAST) announces that the past few weeks have been a very exciting time for Kasten/DAKOTA Life Sciences. The merger brought the DAKOTA experience in the life sciences sector, proprietary technologies, and multiple ready-for-market pharmaceutical products. This includes DAKOTA's prescription development pipeline that is quite advanced in several product areas.
The past few weeks have been a very exciting time for Kasten/DAKOTA Life Sciences (OTC Pink: KAST). The merger brought the DAKOTA experience in the life sciences sector, proprietary technologies, and multiple ready-for-market pharmaceutical products. This includes DAKOTA's prescription development pipeline that is quite advanced in several product areas.
SIOUX FALLS, South Dakota, April 27, 2017 /PRNewswire/ -- Kasten, Inc. (OTC Pink: KAST) has completed its acquisition through the merger of DAKOTA Life Sciences, now a wholly owned subsidiary of Kasten, ...